首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 非專利藥 > 全球生物學名藥市場（2009年∼2014年）
產業/市場分類
製藥 (4495)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (168)
神經疾病 (175)
骨頭疾病治療 (41)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (318)
精神病 (80)
製藥企業 (506)
糖尿病 (157)
癌症 (838)
藥物開發 (1275)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

全球生物學名藥市場（2009年∼2014年）

Biosimilars (2009 - 2014)

出版商 Markets and Markets
出版日期 2009年09月 商品編碼 100546
內容資訊 英文 189 pages
價格
US $ 4650 PDF by E-mail (Single User License)
US $ 5650 PDF by E-mail (Multi User License)
US $ 7150 PDF by E-mail (Corporate Use License)


全球生物學名藥市場（2009年∼2014年） 是由出版商Markets and Markets在2009年09月所出版的。 這份英文市場調查報告書包含189 pages 價格從美金4650起跳。

目錄

Abstract

Report Description

The impending expiry of several patented blockbuster biopharmaceuticals and the increasing demand from patients, insurers, and government agencies to reduce drug costs have created numerous opportunities in the global biosimilars market. The global biosimilars market is expected to be worth US$19.4 billion by 2014, growing at a CAGR of 89.1% from 2009 to 2014. The biosimilars market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others.

The main factors driving the demand in the biosimilars market include increasing user acceptance, low costs and large application area, increasing governmental initiatives, and the emerging Indian and Chinese economies. The major challenges for the biosimilars market are the risks involved with the high investment and the possible failure of the drug during development stages. However, opportunities for biosimilarss market is immense, as biologics worth US$25 billion are going to be off-patent by 2016; and an anticipated approval pathway in U.S. will open up potentially largest market.

Asia' s early commercialization and high absorption rate of biosimilars products made it the dominant market in 2008 with 34.1% share of the global biosimilars market. The American market is expected to dominate in 2014 after the U.S. market opens up in 2010. Currently, the global biosimilars market is highly fragmented with major players such as Biocon, Dr. Reddy' s Lab, Intas, LG LifeSciences, Ranbaxy, Reliance LifeSciences, Sandoz, Teva, and Wockhardt. Favorable regulatory developments in the biosimilars sector are expected to increase the market shares and profit margins while reducing medical expenditure.

Scope of the Report

This report aims to identify and analyze biosimilars market on the basis of products, services, technology, and applications.

  • Biosimilars product market - Peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others
  • Biosimilars service market - Contract research and manufacturing services, clinical trials services
  • Biosimilars applications market - Oncology, infectious diseases, chronic and autoimmune diseases, and other diseases
  • Biosimilars technology market - Recombinant DNA technology, monoclonal antibodies technologies, protein sequencing, bioassay, chromatography, nuclear magnetic resonance, and mass spectrometry

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide more than 60 market tables for various geographic regions covering the sub-segments and micro-markets. In addition, the report also provides 40 company profiles for each of its sub-segments.

What makes our reports unique?
  • We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
  • Each report is about 250 pages with 100+ market data tables, 40 competitive company profiles, analysis of 300 patents and a minimum of 50 micro markets, which are collectively exhaustive and mutually exclusive.
  • No single report by any other publisher provides market data for all the segments viz products, services, applications, ingredients, technology, and stakeholders in a single report for all the four geographies - US, Europe, APAC, ROW (Rest of the World).
  • We provide 10% customization. Normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.
  • 15 pages of high level analysis including benchmarking strategies, best practices and the market' s cash cows (BCG matrix). We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
  • Comprehensive market analysis for the following sectors: Pharmaceuticals, medical devices, biotechnology, semiconductor and electronics, energy and power supplies, food and beverages, chemicals, advanced materials, industrial automation, and telecom and it. we also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered
  • Which are the high-growth segments/cash cows and how is the market segmented in terms of applications, products, services, ingredients, technologies, and stakeholders?
  • What are market estimates and forecasts; which markets are doing well and which are not?
  • Where are the gaps and opportunities; what is driving the market?
  • Which are the key playing fields? Which are the winning edge imperatives?
  • How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts working with MarketsandMarkets come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

Table of Contents

1. INTRODUCTION

  • 1.1. KEY TAKE AWAYS
  • 1.2. REPORT DESCRIPTION
  • 1.3. SCOPE OF THE REPORT
  • 1.4. STAKEHOLDERS

2. SUMMARY

  • 2.1. GLOSSARY

3. MARKET OVERVIEW

  • 3.1. ISSUES RELATED WITH BIOSIMILAR
  • 3.2. DEFINING THE GLOBAL BIOSIMILAR MARKET
  • 3.3. DRIVING FACTOR ANALYSIS
    • 3.3.1. DEMAND-SIDE DRIVERS
    • 3.3.2. SUPPLY-SIDE DRIVERS
    • 3.3.3. RESTRAINTS & OPPORTUNITIES
    • 3.3.4. KEY COMPETITIVE POINTS
  • 3.4. POTENTIAL MATRIX FOR GLOBAL BIOSIMILAR PRODUCTS
  • 3.5. POTENTIAL MATRIX FOR GLOBAL BIOSIMILAR APPLICATIONS
  • 3.6. BIOSIMILAR MARKET DYNAMICS
  • 3.7. COMPARISON OF BIOSIMILAR AND GENERIC DRUGS
  • 3.8. PRICING OF BIOSIMILAR DRUG
  • 3.9. SUPPLY SIDE STAKEHOLDERS
    • 3.9.1. Innovator drug manufacturers
    • 3.9.1. rug device manufacturers & next-generation innovators
  • 3.10.BIOSIMILAR PRODUCTS GEOGRAPHICAL TREN0D
  • 3.11.CYCLE OF INNOVATION AND COMPETITION

4. BIOSIMILAR PRODUCTS SUMMARY

  • 4.1. RECOMBINANT NON-GLYCOSYLATED PROTEIN
    • 4.1.1. DRIVERS
    • 4.1.2. INSULIN
      • 4.1.2.1. Drivers & Opportunities
        • 4.1.2.1.1. Increasing demand from huge patient-base
        • 4.1.2.1.2. Improvements in drug delivery method
    • 4.1.3. RECOMBINANT HUMAN GROWTH HORMONE
    • 4.1.4. LEPIRUDIN
    • 4.1.5. NTERLEUKIN - 2 (IL-2)
    • 4.1.6. INTERFERONS
      • 4.1.6.1. Interferon Alfa
      • 4.1.6.2. Interferon beta-1a
      • 4.1.6.3. Interferon gamma
    • 4.1.7. GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF)
    • 4.1.8. INTERLEUKIN-11
    • 4.1.9. ANAKINRA
  • 4.2. RECOMBINANT GLYCOSYLATED PROTEINS
    • 4.2.1. DRIVERS & RESTRAINTS
      • 4.2.1.1. Applications in many therapeutic indications
      • 4.2.1.2. Segment covers major drug categories
      • 4.2.1.3. Requires high degree of clinical and manufacturing expertise
    • 4.2.2. ERYTHROPOIETIN (EPO)
    • 4.2.3. FOLLITROPIN
    • 4.2.4. HYROTROPIN
    • 4.2.5. UROKINASE
    • 4.2.6. GLUCOCEREBROSIDASE
    • 4.2.7. BECAPLERMIN
    • 4.2.8. GRANULOCYTE-MACROPHAGE-CSF (GM-CSF)
    • 4.2.9 RECOMBINANT HUMAN DNASE (RHDNASE)
    • 4.2.10.FACTOR VIIA
    • 4.2.11.FACTOR VIII
    • 4.2.12.FACTOR IX
    • 4.2.13.ACTIVATED PROTEIN C
    • 4.2.14.TISSUE PLASMINOGEN ACTIVATOR
    • 4.2.15.MONOCLONAL ANTIBODIES
      • 4.2.15.1. Chimaeric Antibodies
      • 4.2.15.2. Humanized / CDR-grafted / Reshaped antibodies
      • 4.2.15.3. Human antibodies and fusion protein
  • 4.3. PEPTIDES
    • 4.3.1. DRIVERS
      • 4.3.1.1. Development of synthetic and biological peptide libraries
      • 4.3.1.2. Fewer side effects and maximum therapeutic index
    • 4.3.2. RESTRAINTS & OPPORTUNITIES
      • 4.3.2.1. Short half-life of peptide molecules
      • 4.3.2.2. Costly manufacturing and purification process
      • 4.3.2.3. Approval of drug candidates in Phase II & III
    • 4.3.3. OCTREOTIDE
    • 4.3.4. DESMOPRESSIN
    • 4.3.5. CYCLOSPORINE
    • 4.3.6. CALCITONIN
    • 4.3.7. EPTIFIBATIDE
    • 4.3.8. LH-RH (LEUPROLIDE)
    • 4.3.9. NESIRITIDE
    • 4.3.10.TERIPARATIDE
    • 4.3.11.BIVALIRUDIN
    • 4.3.12.ENFUVIRTIDE
    • 4.3.13.GLUCAGON

5. BIOSIMILAR SERVICE MARKET SUMMARY

  • 5.1. CONTRACT RESEARCH AND MANUFACTURING SERVICES
    • 5.1.1. DRIVERS
      • 5.1.1.1. Outsourcing non-core activities to low cost destinations
      • 5.1.1.2. Time consuming nature of drug manufacturing
    • 5.1.2. RESTRAINTS & OPPORTUNITIES
      • 5.1.2.1. Long inception period
      • 5.1.2.2. Low returns
      • 5.1.2.3. Emergence of biosimilars
  • 5.2. CLINICAL TRIALS
    • 5.2.1. DRIVERS & RESTRAINTS
      • 5.3.2.1. Extensive information about new drug candidate
      • 5.3.2.2. Central role in drug development
    • 5.2.2. High cost
    • 5.2.3 PHASE I
    • 5.2.4. PHASE II
    • 5.2.5. PHASE III

6. BIOSIMILAR APPLICATION MARKET SUMMARY

  • 6.1. DRIVERS
    • 6.1.1. Prevalence of incurable diseases
    • 6.1.2. xpanding patient population
    • 6.1.3. Developed technology
    • 6.1.4. Increased life expectancy
  • 6.2. RESTRAINTS
    • 6.2.1. Failure of clinical research
    • 6.2.2. Adverse effects of therapies
  • 6.3. ONCOLOGY
    • 6.3.1. DRIVERS
      • 6.3.1.1. Unraveling of the genetics behind cancer
      • 6.3.1.2. Significance and variants
      • 6.3.1.3. Availability of new treatments
      • 6.3.1.4. Increase in the ageing population
    • 6.3.2. RESTRAINTS & OPPORTUNITIES
      • 6.3.2.1. Lack of early stage diagnostic
      • 6.3.2.2. Unawareness and lack of penetration of therapeutics
      • 6.3.2.3. Large product pipeline
    • 6.3.3. LUNG CANCER
    • 6.3.4. COLORECTAL CANCER
    • 6.3.5 BREAST CANCER
    • 6.3.6. CERVICAL CANCER
    • 6.3.7. LEUKEMIA
      • 6.3.7.1. Drivers
        • 6.3.7.1.1. Huge market potential
        • 6.3.7.1.2. Rising awareness
      • 6.3.7.2. PROSTATE CANCER
  • 6.4. INFECTIOUS DISEASES
    • 6.4.1. HIV/AIDS
      • 6.4.1.1. Drivers
        • 6.4.1.1.1. Continual research to increase market size
        • 6.4.1.1.2. Biological drugs increase life expectancy
        • 6.4.1.1.3. Less expensive than biological drugs
        • 6.4.1.1.4. Lack of awareness and access among low income population
    • 6.4.2. HEPATITIS B
    • 6.4.3. EPATITIS C
  • 6.5. CHRONIC AND AUTOIMMUNE DISEASES
    • 6.5.1. DIABETES
      • 6.5.1.1. Drivers
        • 6.5.1.1.1. Awareness & early diagnosis prevents disease development
        • 6.5.1.1.2. Changing approach of patients towards medication
    • 6.5.2. NEUTROPENIA
    • 6.5.3. MULTIPLE SCLEROSIS
      • 6.5.3.1. Drivers
        • 6.5.3.1.1. Rising awareness
        • 6.5.3.1.2. Increases the life expectancy
        • 6.5.3.1.3. Inhibitors and opportunities
    • 6.5.4. CYSTIC FIBROSIS
    • 6.5.5. RHEUMATOID ARTHRITIS (RA)
      • 6.5.5.1. Drivers
        • 6.5.5.1.1. Large patient population
        • 6.5.5.1.2. Need for continued treatment
      • 6.5.5.2. Restraints
    • 6.5.6. ACROMEGALY
      • 6.5.6.1. Driver
        • 6.5.6.1.1. Risk of getting other diseases
        • 6.5.6.1.2. Worldwide prevalence of the disease
    • 6.5.7. LEPROSY
  • 6.6. HEMATOLOGY
    • 6.6.1. DRIVERS
      • 6.6.1.1. Prevalence of blood-related disorders
      • 6.6.1.2. Availability of cheaper treatment alternatives
      • 6.6.1.3. Early start of medication and longer treatment time
    • 6.6.2. CHEMOTHERAPY INDUCED ANEMIA
      • 6.6.2.1. Drivers
        • 6.6.2.1.1. Chemotherapy has become the preferred treatment
        • 6.6.2.1.2. Availability of new treatment alternatives
        • 6.6.2.1.3. Early and easy diagnostics drives the market
      • 6.6.2.2. Restraints and Opportunities
    • 6.6.3. HEMOPHILIA
    • 6.5.4. PULMONARY EMBOLISM
      • 6.6.4.1. Drivers
        • 6.6.4.1.1. Availability of large number of diagnosis tools
        • 6.6.4.1.2. Need for immediate medication
  • 6.7. GROWTH HORMONE DEFICIENCY (GHD)
    • 6.7.1. DRIVERS
      • 6.7.1.1. Natural deficiency of GH and destruction of normal pituitary gland
      • 6.7.1.2. Need for body mass management
      • 6.7.1.3. Changes in the body composition
  • 6.8. OTHER DISEASES
    • 6.8.1. GAUCHER DISEASE
    • 6.8.2. OSTEOPOROSIS
    • 6.8.3. FERTILITY DISORDERS (INFERTILITY)
    • 6.8.4. SKIN ULCER
    • 6.8.5. HYPOGLYCEMIA
    • 6.8.6. NOCTURNAL ENURESIS
    • 6.8.7. CONGESTIVE HEART FAILURE (CHF)
    • 6.8.8. SYSTEMIC SEPSIS
    • 6.8.9. OTHERS

7. BIOSIMILAR TECHNOLOGY SUMMARY

  • 7.1. MONOCLONAL ANTIBODIES (MAB) TECHNOLOGY
    • 7.1.1. DRIVERS
      • 7.1.1.1. Broad range of therapeutic, diagnostic, and research applications
      • 7.1.1.2. Low cost of development
      • 7.1.1.3. Higher success rate
    • 7.1.2. TOP PLAYER ANALYSIS
  • 7.2. RECOMBINANT DNA TECHNOLOGY (RDNA TECHNOLOGY)
    • 7.2.1. DRIVERS
      • 7.2.1.1. Human therapeutics application
      • 7.2.1.2. Agricultural genetic engineering application
      • 7.2.1.3. Increase in demand of biopharmaceutical products
    • 7.2.2. RESTRAINTS & OPPORTUNITIES
      • 7.2.2.1. High Cost
      • 7.2.2.2. Risk of failure
      • 7.2.2.3. Role in production of edible vaccines
  • 7.3. CHROMATOGRAPHY
    • 7.3.1. DRIVERS & OPPORTUNITIES
      • 7.3.1.1. High resolution refinement
      • 7.3.1.2. Efficacy of end product
      • 7.3.1.3. Wide applications
      • 7.3.1.4. Emergence of biosimilars
    • 7.3.2. TOP PLAYER ANALYSIS
    • 7.3.3. LIQUID CHROMATOGRAPHY (LC)
    • 7.3.4. GAS CHROMATOGRAPHY (GC)
  • 7.4. PROTEIN SEQUENCING
    • 7.4.1. DRIVERS
      • 7.4.1.1. Applications in life saving drug development
      • 7.4.1.2. Applications in protein classification
      • 7.4.1.3. Use in diagnosis
  • 7.5. NUCLEAR MAGNETIC RESONANCE (NMR) TECHNOLOGY
    • 7.5.1. DRIVERS
      • 7.5.1.1. Leading technology for 3-D structure
      • 7.5.1.2. Eliminates risk of x-radiation
      • 7.5.1.3. Application in drug delivery system
  • 7.6. ELECTROPHORESIS
    • 7.6.1. DRIVERS
      • 7.6.1.1. Genomic application
      • 7.6.1.2. Most reliable technique
      • 7.6.1.3. Separation Efficacy
    • 7.6.2. RESTRAINTS & OPPORTUNITIES
      • 7.6.2.1. High sample runtime
    • 7.6.3. GEL ELECTROPHORESIS
    • 7.6.4. CAPILLARY ELECTROPHORESIS
  • 7.7. MASS SPECTROMETRY
    • 7.7.1. DRIVERS
      • 7.7.1.1. Simple Quantification of Protein Structures
      • 7.7.1.2. Supporting Element for Growing Technologies:
      • 7.7.1.3. Gaining Popularity of Hybrid Mass Spectrometry Instruments
    • 7.7.2. RESTRAINTS
      • 7.7.2.1. Fails to Analyze Small Quantities of Proteins
      • 7.7.2.2. Manual Interruption Necessary, Increasing the Error Rate
  • 7.8. WESTERN BLOTTING
    • 7.8.1. DRIVERS
      • 7.8.1.1. Application in molecular biology disciplines
      • 7.8.1.2. Application in diagnosis of diseases
      • 7.8.1.3. High efficacy at low cost
  • 7.9. BIOASSAY
    • 7.9.1. DRIVERS
      • 7.9.1.1. Central role in new drug development
      • 7.9.1.2. Monitoring environmental pollutants
      • 7.9.1.3. Cost benefits and error reduction
      • 7.9.1.4. Shrinking pipelines of new drug candidates
      • 7.9.1.5. Increasing price pressures in the U.S. and Europe
    • 7.9.2. RESTRAINTS
      • 7.9.2.1. Accuracy of experiment not guaranteed
      • 7.9.2.2. Time-consuming, laborious, and organism-specific activity
    • 7.9.3. TECHNIQUES IN BIOASSAY
      • 7.9.3.1. Six Point Assay
      • 7.9.3.2. Multiple Point Assays
      • 7.9.3.3. Interpolation Method
      • 7.9.3.4. Bracketing Method
      • 7.9.3.5. Matching Bioassays

8. GEOGRAPHIC ANALYSIS

  • 8.1. AMERICAN BIOSIMILAR MARKET
    • 8.1.1. Large patient base and high Medicare expenditure
    • 8.1.2. Largest Biopharmaceutical market
  • 8.2. EUROPEAN BIOSIMILAR MARKET
  • 8.3. ASIAN BIOSIMILAR MARKET
  • 8.4. ROW BIOSIMILAR MARKET

9. REGULATORY GUIDELINES

  • 9.1. AMERICA
    • 9.1.1. CANADA
    • 9.1.2. U.S.
  • 9.2. ASIA
    • 9.2.1. JAPAN
    • 9.2.2. HINA
    • 9.2.3. NDIA
    • 9.2.4. UROPE
    • 9.2.5. ROW

10.COMPANY PROFILES

  • 10.1. 3SBIO (SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD)
  • 10.2. ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD
  • 10.3. BHARAT BIOTECH
  • 10.4. BIOCLONES (PTY) LTD.
  • 10.5. BIOCON
  • 10.6. BIOGNERIX AG
  • 10.7. BIOPARTNERS
  • 10.8. CANGENE
  • 10.9. CINNAGEN INC.
  • 10.10. CLARIS LIFESCIENCES
  • 10.11. DONG-A PHARMACEUTICAL
  • 10.12. DR. REDDY' S LABORATORIES
  • 10.13. DSM BIOLOGICS
  • 10.14. DYNAVAX TECHNOLOGIES
  • 10.15. EMCURE
  • 10.16. GENESCIENCE PHARMACEUTICALS CO LTD.
  • 10.17. GLENMARK PHARMACEUTICALS
  • 10.18. GTC BIOTHERAPEUTICS LTD.
  • 10.19. HOSPIRA INC.
  • 10.20. INTAS BIOPHARMACEUTILCALS LTD.
  • 10.21. LG LIFE SCIENCES
  • 10.22. MAXYGEN
  • 10.23. MERCK
  • 10.24. MOMENTA
  • 10.25. PANACEA BIOTECH
  • 10.26. PHAGE BIOTECH CORPORATION
  • 10.27. PHARMACLON
  • 10.28. PROLONG PHARMACEUTICALS
  • 10.29. RANBAXY
  • 10.30. RELIANCE GENEMEDIX PLC 1
  • 10.31. SANDOZ (NOVARTIS PHARMACEUTICAL)
  • 10.32. SCIGEN
  • 10.33. SCINOPHARM TAIWAN, LTD.
  • 10.34. SHANTHA BIOTECH
  • 10.35. SHENZHEN NEPTUNUS INTERLONG
  • 10.36. SHREYA LIFE SCIENCES LTD.
  • 10.37. STADA ARZNEIMITTEL AG
  • 10.38. TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 10.39. VIROPRO INTERNATIONAL INC.
  • 10.40. WOCKHARDT LIMITED

11.PATENT ANALYSIS

  • 11.1. PATENT EXPIRATION IN 2008 AND BEFORE
  • 11.2. PATENT EXPIRATION IN 2009 AND AFTER

APPENDIX

  • PATENT EXPIRY IN 2008 AND BEFORE
  • U.S. BIOPHARMACEUTICAL PATENTS
  • EUROPEAN BIOPHARMACEUTICAL PATENTS
  • ASIAN BIOPHARMACEUTICAL PATENTS
  • PATENT EXPIRY IN 2009 AND AFTER
  • U.S. BIOPHARMACEUTICAL PATENTS
  • EUROPEAN BIOPHARMACEUTICAL PATENTS
  • ASIAN BIOPHARMACEUTICAL PATENTS

LIST OF TABLES

  • SUMMARY TABLE GLOBAL BIOSIMILAR MARKET, BY PRODUCTS 2007 - 2014($ THOUSANDS)
  • TABLE 1. GLOBAL BIOSIMILAR NON-GLYCOSYLATED PROTEIN MARKET, BY PRODUCT 2007 - 2014 ($ THOUSANDS)
  • TABLE 2. GLOBAL BIOSIMILAR RECOMBINANT NON-GLYCOSYLATED PROTEIN MARKET, BY GEOGRAPHY 2007 - 2014 ($ THOUSANDS)
  • TABLE 3. MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
  • TABLE 4. GLOBAL BIOSIMILAR RECOMBINANT INSULIN MARKET, BY GEOGRAPHY2007 - 2014 ($ THOUSANDS)
  • TABLE 5. GLOBAL BIOSIMILAR RHGH MARKET, BY GEOGRAPHY 2007 - 2014($ THOUSANDS)
  • TABLE 6. GLOBAL BIOSIMILAR LEPIRUDIN MARKET, BY GEOGRAPHY 2007 - 2014($ THOUSANDS)
  • TABLE 7. GLOBAL BIOSIMILAR RECOMBINANT INTERLEUKIN - MARKET, BY GEOGRAPHY 2007 - 2014 ($ THOUSANDS)
  • TABLE 8. GLOBAL BIOSIMILAR RECOBINANT INTERFERONS MARKET, BY PRODUCT2007 - 2014 ($ THOUSANDS)
  • TABLE 9. GLOBAL BIOSIMILAR RECOMBINANT INTERFERONS MARKET, BY GEOGRAPHY 2007 - 2014 ($ THOUSANDS)
  • TABLE 10. GLOBAL BIOSIMILAR RECOMBINANT INTERFERON ALFA MARKET BY GEOGRAPHY 2007 - 2014 ($ THOUSANDS)
  • TABLE 11. GLOBAL BIOSIMILAR RECOMBINANT INTERFERON BETA- 1A MARKET, BY GEOGRAPHY 2007 - 2014 ($ THOUSANDS)
  • TABLE 12. GLOBAL BIOSIMILAR RECOMBINANT INTERFERON GAMMA MARKET, BY GEOGRAPHY 2007 - 2014 ($ THOUSANDS)
  • TABLE 13. GLOBAL BIOSIMILAR RECOMBINANT GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) MARKET, BY GEOGRAPHY 2007 - 2014 ($ THOUSANDS)
  • TABLE 14. GLOBAL BIOSIMILAR RECOMBINANT INTERLEUKIN- 11 MARKET, BY GEOGRAPHY 2007 - 2014 ($ THOUSANDS)
  • TABLE 15. GLOBAL BIOSIMILAR RECOMBINANT ANAKINRA MARKET, BY GEOGRAPHY2007 - 2014 ($ THOUSANDS)
  • TABLE 16. GLOBAL BIOSIMILAR GLYCOSYLATED PROTEIN MARKET, BY PRODUCTS2007 - 2014 ($ THOUSANDS)
  • TABLE 17. GLOBAL BIOSIMILAR GLYCOSYLATED PROTEIN MARKET, BY GEOGRAPHY2007 - 2014 ($ THOUSANDS)
  • TABLE 18. MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
  • TABLE 19. GLOBAL BIOSIMILAR RECOMBINANT EPO MARKET, BY GEOGRAPHY2007 - 2014 ($ THOUSANDS)
  • TABLE 20. GLOBAL BIOSIMILAR FOLLITROPIN MARKET, BY GEOGRAPHY2007 - 2014 ($ THOUSANDS)
  • TABLE 21. GLOBAL BIOSIMILAR THYROTROPIN MARKET, BY GEOGRAPHY 2007 - 2014 ($ THOUSANDS)
  • TABLE 22. GLOBAL BIOSIMILAR UROKINASE MARKET, BY GEOGRAPHY 2007 - 2014($ THOUSANDS) 61
  • TABLE 23. GLOBAL BIOSIMILAR GLUCOCEREBROSIDASE MARKET, BY GEOGRAPHY2007 - 2014 ($ THOUSANDS)
  • TABLE 24. GLOBAL BIOSIMILAR BECAPLERMIN MARKET, BY GEOGRAPHY 2007 - 2014 ($ THOUSANDS)
  • TABLE 25. GLOBAL BIOSIMILAR RECOMBINANT GM-CSF MARKET, BY GEOGRAPHY2007 - 2014 ($ THOUSANDS)
  • TABLE 26. GLOBAL BIOSIMILAR RHDNASE MARKET, BY GEOGRAPHY 2007 - 2014($ THOUSANDS)
  • TABLE 27. GLOBAL BIOSIMILAR FACTOR VIIA MARKET, BY GEOGRAPHY 2007 - 2014($ THOUSANDS)
  • TABLE 28. GLOBAL BIOSIMILAR FACTOR VIII MARKET, BY GEOGRAPHY 2007 - 2014($ THOUSANDS)
  • TABLE 29. GLOBAL BIOSIMILAR FACTOR IX MARKET, BY GEOGRAPHY 2007 - 2014($ THOUSANDS)
  • TABLE 30. GLOBAL BIOSIMILAR ACTIVATED PROTEIN C MARKET, BY GEOGRAPHY 2007 - 2014 ($ THOUSANDS)
  • TABLE 31. GLOBAL BIOSIMILAR TPA MARKET, BY GEOGRAPHY 2007 - 2014($ THOUSANDS)
  • TABLE 32. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, BY GEOGRAPHY 2007 - 2014 ($ THOUSANDS)
  • TABLE 33. GLOBAL BIOSIMILAR PEPTIDE MARKET, BY PRODUCTS 2007 - 2014($ THOUSANDS)
  • TABLE 34. GLOBAL BIOSIMILAR PEPTIDE MARKET, BY GEOGRAPHY 2007 - 2014($ THOUSANDS)
  • TABLE 35. MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
  • TABLE 36. GLOBAL BIOSIMILAR OCTREOTIDE PEPTIDE MARKET, BY GEOGRAPHY2007 - 2014 ($ THOUSANDS)
  • TABLE 37. GLOBAL BIOSIMILAR DESMOPRESSIN PEPTIDE MARKET, BY GEOGRAPHY2007 - 2014 ($ THOUSANDS)
  • TABLE 38. GLOBAL BIOSIMILAR CYCLOSPORINE PEPTIDE MARKET, BY GEOGRAPHY 2007 - 2014 ($ THOUSANDS)
  • TABLE 39. GLOBAL BIOSIMILAR CALCITONIN PEPTIDE MARKET, BY GEOGRAPHY2007 - 2014 ($ THOUSANDS)
  • TABLE 40. GLOBAL BIOSIMILAR EPTIFIBATIDE PEPTIDE MARKET, BY GEOGRAPHY2007 - 2014 ($ THOUSANDS)
  • TABLE 41. GLOBAL BIOSIMILAR LH-RH PEPTIDE MARKET, BY GEOGRAPHY 2007 - 2014 ($ THOUSANDS)
  • TABLE 42. GLOBAL BIOSIMILAR NESIRITIDE PEPETIDE MARKET, BY GEOGRAPHY2007 - 2014 ($ THOUSANDS)
  • TABLE 43. GLOBAL BIOSIMILAR TERIPARATIDE PEPTIDE MARKET, BY GEOGRAPHY2007 - 2014 ($ THOUSANDS)
  • TABLE 44. GLOBAL BIOSIMILAR BIVALIRUDIN PEPTIDE MARKET, BY GEOGRAPHY2007 - 2014 ($ THOUSANDS)
  • TABLE 45. GLOBAL BIOSIMILAR ENFUVIRTIDE PEPTIDE MARKET, BY GEOGRAPHY2007 - 2014 ($ THOUSANDS)
  • TABLE 46. GLOBAL BIOSIMILAR GLUCAGON PEPTIDE MARKET, BY GEOGRAPHY2007 - 2014 ($ THOUSANDS)
  • TABLE 47. MAJOR PLAYERS AND DEVELOPMENTS
  • TABLE 48. GLOBAL BIOSIMILAR MARKET, BY APPLICATIONS 2007 - 2014($ THOUSANDS)
  • TABLE 49. GLOBAL BIOSIMILAR ONCOLOGY MARKET, BY TYPES 2007 - 2014($ THOUSANDS)
  • TABLE 50. GLOBAL BIOSIMILAR INFECTIOUS DISEASES MARKET, BY TYPES 2007 - 2014 ($ THOUSANDS)
  • TABLE 51. GLOBAL BIOSIMILAR CHRONIC AND AUTOIMMUNE DISEASE MARKET, BY TYPES 2007 - 2014 ($ THOUSANDS)
  • TABLE 52. GLOBAL BIOSIMILAR HEMATOLOGY MARKET, BY TYPES 2007 - 2014($ THOUSANDS)
  • TABLE 53. GLOBAL BIOSIMILAR OTHER DISIEASES MARKET, BY TYPES 2007 - 2014($ THOUSANDS)
  • TABLE 54. MAJOR PLAYERS AND DEVELOPMENTS
  • TABLE 55. MAJOR PLAYERS AND DEVELOPMENTS
  • TABLE 56. GLOBAL BIOSIMILAR MARKET, BY GEOGRAPHY 2007 - 2014 ($ THOUSANDS)
  • TABLE 57. AMERICAN BIOSIMILAR MARKET, BY SEGMENTS 2007 - 2014($ THOUSANDS)
  • TABLE 58. EUROPEAN BIOSIMILAR MARKET, BY SEGMENTS 2007 - 2014($ THOUSANDS)
  • TABLE 59. ASIAN BIOSIMILAR MARKET, BY SEGMENTS 2007 - 2014 ($ THOUSANDS)
  • TABLE 60. ROW BIOSIMILAR MARKET, BY SEGMENTS 2007 - 2014 ($ THOUSANDS)

LIST OF FIGURES

  • FIGURE 1. MARKET TRANSITION IMPACTING BIOSIMILAR MARKET
  • FIGURE 2. ISSUES RELATED WITH BIOSIMILAR
  • FIGURE 3. BIOSIMILAR MARKET DEFINITION
  • FIGURE 4. DRIVING FACTOR ANALYSIS OF GLOBAL BIOSIMILAR MARKET
  • FIGURE 5. MARKET POTENTIAL MATRIX FOR GLOBAL BIOSIMILAR PRODUCT MARKET, 2009
  • FIGURE 6. MARKET POTENTIAL MATRIX FOR GLOBAL BIOSIMILAR APPLICATION MARKET, 2009
  • FIGURE 7. GLOBAL BIOSIMILAR MARKET DYNAMICS
  • FIGURE 8. COMPARISON OF BIOSIMILAR AND GENERIC DRUGS
  • FIGURE 9. PRICING OF BIOSIMILAR DRUG
  • FIGURE 10. SUPPLY SIDE STAKEHOLDERS
  • FIGURE 11. BIOSIMILAR PRODUCTS GEOGRAPHICAL TREND
  • FIGURE 12. CYCLE OF INNOVATION AND COMPETITION
  • FIGURE 13. BIOSIMILAR PRODUCT MARKET TREND
  • FIGURE 14. EUROPEAN BIOSIMILAR MARKET DYNAMICS
  • FIGURE 15. GLOBAL BIOPHARMACEUTICAL PATENTS, BY SEGMENT
  • FIGURE 16. GLOBAL BIOPHARMACEUTICAL PATENTS, BY GEOGRAPHY
  • FIGURE 17. U.S. BIOPHARMACEUTICAL PATENTS, BY SEGMENT
  • FIGURE 18. EUROPE BIOPHARMACEUTICAL PATENTS, BY SEGMENT
  • FIGURE 19. ASIA BIOPHARMACEUTICAL PATENTS, BY SEGMENT
  • FIGURE 20. GLOBAL BIOPHARMACEUTICAL PATENTS, BY SEGMENT
  • FIGURE 21. GLOBAL BIOPHARMACEUTICAL PATENTS, BY GEOGRAPHY
  • FIGURE 22. U.S. BIOPHARMACEUTICAL PATENTS, BY SEGMENT
  • FIGURE 23. EUROPE BIOPHARMACEUTICAL PATENTS, BY SEGMENT
  • FIGURE 24. ASIA BIOPHARMACEUTICAL PATENTS, BY SEGMENT

LIST OF ACRONYMS AND ABBREVIATIONS

  • ADR - Adverse Drug Reactions
  • AIDS - Acquired Immunodeficiency Syndrome
  • ALL - Acute Lymphoblastic Leukemia
  • AML - Acute Myelogenous Leukemia
  • ANDA - Abbreviated New Drug Applications
  • API - Active Pharmaceutical Ingredients
  • CAGR - Compound Annual Growth Rate
  • CBC - Complete Blood Count
  • CF - Cystic Fibrosis
  • CHF - Congestive Heart Failure
  • CHMP - Committee for Medicinal Products for Human Use
  • CLL - Chronic Lymphocytic Leukemia
  • CML - Chronic Myelogenous Leukemia
  • CRAMS - Contract Research And Manufacturing Services
  • CZE - Capillary Zone Electrophoresis
  • DI - Diabetes Insipidus
  • DNA - Deoxyribo Nucleic Acid
  • EBA - Expanded Bed Absorption
  • ELISPOT - Enzyme-linked Immunosorbent Spot
  • EMEA - European Medicines Evaluation Agency
  • ENF - Enfuvirtide
  • EPO - Erythropoietin
  • ERT - Estrogen Replacement Therapy
  • EU - European Union
  • FDA - Food and Drugs Administration
  • GC - Gas Chromatography
  • GH - Growth Hormone
  • GHD - Growth Hormone Deficiency
  • GP - Glycoprotein
  • HAMA - Human Anti-Mouse Antibody
  • HCV - Hepatitis C Virus
  • HD - Hansen' s Disease
  • hGH - Human Growth Harmone
  • HIT - Heparin Induced Thrombocytopenia
  • HIV - Human Immunodeficiency Virus
  • HPV - Human Papillomavirus
  • IF - Interferon
  • IL - Interleukin
  • IND - Investigational New Drug
  • IUGR - Intrauterine Growth Retardation
  • KBA - Kansas Bioscience Authority
  • LC - Liquid Chromatography
  • LHRH - Latinizing and Releasing Hormone
  • LMWH - Low Molecular weight Heparin
  • MAB - Monoclonal Antibodies
  • MMF - Mycophenolate Mofetil
  • MS - Multiple Sclerosis
  • NDS - New Drug Submission
  • NE - Nocturnal Enuresis
  • NHL - Non-Hodgkin' s lymphoma
  • NMR - Nuclear Magnetic Resonance
  • NTG - Nitroglycerine
  • PCI - Percutaneous Coronary Intervention
  • PE - Pulmonary Embolism
  • PTCA - Percutaneous Transluminal Coronary Angioplasty
  • R&D - Research and Development
  • RA - Rheumatoid Arthritis
  • RCC - Renal Cell Carcinoma
  • RFLP - Restriction Fragment Length Polymorphism
  • RHDNASE - Recombinant Human DNase
  • RMS - Relapsing Multiple Sclerosis
  • SBIR - Small Business Innovation Research
  • SEB - Subsequent Entry Biologics
  • SLE - Systemic Lupus Erythematosus
  • THST - Thyroid Hormone Suppression Therapy
  • tPA - Tissue Plasminogen Activator
  • TSQ - Triple Stage Quad
  • WHO - World Health Organization
Back to Top